Pluri Inc. Common Stock (PLUR)

FairStock Score: 17/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Pluri is a 92-employee biotechnology company developing placenta-based cell therapies, including PLX-PAD. It is a story of scientific hope, not current business earnings. In fiscal 2026, the year ended 2026-06-30, revenue was $1.0 million, down from $1.3 million in fiscal 2025, after $326,000 in fiscal 2024. Net losses were $23.8 million, $22.6 million, and $20.9 million, respectively. Diluted EPS improved from -$3.99 to -$3.56 to -$2.44, but losses remained enormous. The latest filed quarters show tiny revenue: $316,000 in fiscal Q1 2026, $198,000 in fiscal Q2 2026, and $167,000 in fiscal Q3 2026. I see no durable earnings power and no competitive moat in these numbers. Financial health is poor. Trailing free cash flow is negative $20.2 million, a FairStock calculation, and FCF yield is -174.3% against an $11.6 million market cap. Altman Z-score is -27.99, Piotroski F-score is 3/9, and the FairStock Score is 17/100. ROCE is -49.04%, another FairStock calculation. At the 2026-10-13 close of $0.94, the FairStock P/E is -0.39, which is meaningless without profits. A beta of 0.69 does not reduce fundamental risk. Growth depends on clinical and regulatory events and financing, not on revenue growth; filed revenue fell in fiscal 2026. Graham wanted assets, earnings, and a margin of safety. Buffett wanted a moat and owner earnings. This has neither today. The bull case is pipeline success and new capital; the bear case is continued dilution and failure.

In plain English: Pluri is a small biotechnology company that works on cell-based therapies made from placenta. The business looks weak: it brings in very little money and loses millions each year. The stock price is very low, but with no profits and heavy spending, it is hard to call it cheap based on the numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer